Regorafenib

Apr 28, 2020

Blueprint Medicines Announces Top-line Results from Phase 3 VOYAGER Trial of Avapritinib versus Regorafenib in Patients with Advanced Gastrointestinal Stromal Tumor

Jan 24, 2020

CStone announces first patient dosed in the global proof-of-concept study of CS1001 in combination with Bayer's regorafenib

Oct 28, 2019

Blueprint Medicines Announces FDA Intent to Split Avapritinib New Drug Application into Separate Submissions for PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST

Sep 20, 2019

Bayer data at ESMO 2019 highlights innovation in cancer research

Jun 19, 2019

Bayer's Stivarga® (regorafenib) becomes first compound used in clinical trial platform to investigate new therapies for brain cancer

Jun 09, 2019

CStone and Bayer announce global collaboration to evaluate PD-L1 monoclonal antibody CS1001 in combination with regorafenib

Oct 09, 2018

Bayer to Showcase Latest Oncology Research at ESMO 2018 Congress

Sep 28, 2018

Taiho Oncology Presents Real-World Adherence Data for LONSURF® (trifluridine and tipiracil) in Metastatic Colorectal Cancer at ASCO Quality of Care Symposium

Jun 25, 2018

Highlights of the ESMO 20th World Congress on Gastrointestinal Cancer

Jan 17, 2018

Bayer to Highlight New Research at ASCO GI 2018 Cancer Symposium

Sep 01, 2017

Bayer to Highlight New Research at ESMO 2017 Congress